Doctors ID rare pancreatic neuroendocrine tumor in girl, 17
Doctors should consider the possibility of a pancreatic neuroendocrine tumor (pNET) when patients with a history of abdominal and back pain seek treatment. That’s…
Lindsey Shapiro, PhD, science writer — 
Articles by Lindsey Shapiro
Carvykti found effective at treating multiple myeloma in real world
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
Carvykti lowering risk of death as second-line myeloma therapy: Trial
A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
FDA approves Sarclisa regimen as first-line treatment for myeloma
The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…
Ready-to-use bortezomib formula Boruzu OK’d for multiple myeloma
The U.S. Food and Drug Administration (FDA) has approved Boruzu, a ready-to-use injectable formulation of bortezomib, for treating adults with multiple myeloma and mantle…
Blood Cancer Awareness Month is an opportunity to #kNOwMyeloma
Supporters are gearing up to learn, educate, and fundraise in observance of Blood Cancer Awareness Month, which is held each September to increase awareness…
FDA adds Darzalex Faspro to combo therapy for newly diagnosed MM
The U.S. Food and Drug Administration (FDA) has approved a new quadruple regimen including Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a first-line approach for adults…
Analyses identify proteins tied to multiple myeloma disease course
Researchers in Germany have identified proteins that could help identify multiple myeloma patients who at high risk for an aggressive disease course and worse…
Blenrep lowers risk of disease progression vs. bortezomib in trial
GSK‘s Blenrep (belantamab mafodotin) cut the risk of cancer progression nearly in half compared with bortezomib when used in combination with other therapies to…
CAR T-cell therapy NXC-201 given orphan drug status in EU
NXC-201, an investigational CAR T-cell therapy, has been designated an orphan drug in the European Union (EU) as a potential treatment of multiple myeloma.